onalespib (AT13387) / Otsuka  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
onalespib (AT13387) / Otsuka
NCT01294202: A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST

Checkmark ASCO-GI 2013
Jan 2013 - Jan 2013: ASCO-GI 2013
Completed
2
26
US
AT13387 and Imatinib, Gleevec
Astex Pharmaceuticals, Inc.
Gastrointestinal Stromal Tumor (GIST)
04/13
07/14
NCT02572453: Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL

Terminated
2
25
US
Onalespib, AT 13387, AT-13387, AT13387
National Cancer Institute (NCI)
Recurrent Anaplastic Large Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
03/21
03/21
NCT01685268 / 2012-001574-28: A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Completed
1/2
49
Europe, Canada, US
AT13387, onalespib, abiraterone acetate, Prednisone, prednisolone
Astex Pharmaceuticals, Inc.
Prostate Cancer
07/14
12/14
NCT01712217 / 2012-001575-37: A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Checkmark From study AT13387 of crizotinib in combination with onalespib in NSCLC at ASCO 2016
Jun 2016 - Jun 2016: From study AT13387 of crizotinib in combination with onalespib in NSCLC at ASCO 2016
Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark ASCO 2016
More
Completed
1/2
220
Europe, Canada, US, RoW
AT13387, Crizotinib, Xalkori
Astex Pharmaceuticals, Inc.
Non-small Cell Lung Cancer(NSCLC)
12/16
05/17
NCT02535338: Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Active, not recruiting
1/2
11
US
Erlotinib Hydrochloride, CP 358, CP-358, Cp-358,774, CP358, OSI 774, OSI-774, OSI774, Tarceva, Laboratory Biomarker Analysis, Onalespib Lactate, AT-13387 Lactate, ATI-13387A, ATI-13387AU, Pharmacological Study
National Cancer Institute (NCI)
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
09/21
09/24

Download Options